Ascend Laboratories recalls

Ascend Laboratories has 50 recalls on record with the FDA and USDA, the earliest in 2016 and the latest reported on 5 Aug 2026. 28 are still ongoing. 14 were reported in the last 12 months. The most frequent reason is potency & assay.

Total recalls50since 2016

Last 12 months14reported

Class I00% of total

Ongoing28latest 5 Aug 2026

Recalls per month, last 24 months

click a bar for that month

1Oct '24 0 2 0Jan '25 0 0 0Apr 0 2 2Jul 1 1 4Oct 0 0 0Jan '26 0 0 0Apr 1 2 3Jul 3 0

Severity split

Class I 0 0%Class II 41 82%Class III 9 18%

Why ascend laboratories is recalled

Product types

Brands

By year

2026918%
20251020%
2024510%
2023918%
202224%
2021714%
202036%
201924%
201812%
201712%

Ongoing ascend laboratories recalls

28 active

Reported	Class	Recall	Company	Reason	Where
5 Aug 2026Drug	CLASS III	Dabigatran Etexilate Capsules, 150 mg recalled by Ascend LaboratoriesDabigatran Etexilate	Ascend Laboratories	Potency & Assay	Nationwide
5 Aug 2026Drug	CLASS III	Dabigatran Etexilate Capsules, 75 mg recalled by Ascend LaboratoriesDabigatran Etexilate	Ascend Laboratories	Potency & Assay	Nationwide
5 Aug 2026Drug	CLASS III	Dabigatran Etexilate Capsules, 75 mg recalled by Ascend LaboratoriesDabigatran Etexilate	Ascend Laboratories	Potency & Assay	Nationwide
29 Jul 2026Drug	CLASS III	Dabigatran etexilate Capsules, 110 mg recalled by Ascend LaboratoriesDabigatran Etexilate	Ascend Laboratories	Potency & Assay	Nationwide
29 Jul 2026Drug	CLASS II	Amlodipine and Olmesartan Medoxomil Tablets, 10 mg/20 mg recalledAmlodipine And Olmesartan Medoxomil	Ascend Laboratories	Potency & Assay	Nationwide
29 Jul 2026Drug	CLASS III	Dabigatran etexilate Capsules, 150 mg recalled by Ascend LaboratoriesDabigatran Etexilate	Ascend Laboratories	Potency & Assay	Nationwide

All ascend laboratories recalls, newest first

50 total

Reported	Class	Recall	Company	Reason	Where
5 Aug 2026Drug	CLASS III	Dabigatran Etexilate Capsules, 150 mg recalled by Ascend LaboratoriesDabigatran Etexilate	Ascend Laboratories	Potency & Assay	Nationwide
5 Aug 2026Drug	CLASS III	Dabigatran Etexilate Capsules, 75 mg recalled by Ascend LaboratoriesDabigatran Etexilate	Ascend Laboratories	Potency & Assay	Nationwide
5 Aug 2026Drug	CLASS III	Dabigatran Etexilate Capsules, 75 mg recalled by Ascend LaboratoriesDabigatran Etexilate	Ascend Laboratories	Potency & Assay	Nationwide
29 Jul 2026Drug	CLASS III	Dabigatran etexilate Capsules, 110 mg recalled by Ascend LaboratoriesDabigatran Etexilate	Ascend Laboratories	Potency & Assay	Nationwide
29 Jul 2026Drug	CLASS II	Amlodipine and Olmesartan Medoxomil Tablets, 10 mg/20 mg recalledAmlodipine And Olmesartan Medoxomil	Ascend Laboratories	Potency & Assay	Nationwide
29 Jul 2026Drug	CLASS III	Dabigatran etexilate Capsules, 150 mg recalled by Ascend LaboratoriesDabigatran Etexilate	Ascend Laboratories	Potency & Assay	Nationwide
17 Jun 2026Drug	CLASS II	Minocycline Hydrochloride Extended-Release Tablets, USP, 115 mg recalledMinocycline Hydrochloride	Ascend Laboratories	Potency & Assay	Nationwide
10 Jun 2026Drug	CLASS II	Amlodipine and Olmesartan Medoxomil Tablets, 5mg/40mg recalledAmlodipine And Olmesartan Medoxomil	Ascend Laboratories	Potency & Assay	Nationwide
20 May 2026Drug	CLASS II	Metoprolol Succinate Extended-Release Tablets, USP, 25 mg* recalledMetoprolol Succinate	Ascend Laboratories	Potency & Assay	Nationwide
22 Oct 2025Drug	CLASS II	Atorvastatin Calcium Tablets USP, 40 mg recalled by Ascend LaboratoriesAtorvastatin Calcium	Ascend Laboratories	Potency & Assay	Nationwide

About this list

Records come from FDA enforcement reports and USDA FSIS notices, grouped by normalised name. A company operating under several names may appear more than once.